181 related articles for article (PubMed ID: 2122290)
1. Three-dose vaccination of infants under 8 months of age with a conjugate Haemophilus influenzae type B vaccine.
Rowe JE; Messinger IK; Schwendeman CA; Popejoy LA
Mil Med; 1990 Oct; 155(10):483-6. PubMed ID: 2122290
[TBL] [Abstract][Full Text] [Related]
2. National Advisory Committee on Immunization (NACI). Statement on Haemophilus influenzae type B conjugate vaccines for use in infants and children.
Can Commun Dis Rep; 1992 Dec; 18(23):169-76. PubMed ID: 1291012
[TBL] [Abstract][Full Text] [Related]
3. Response of 7- to 15-month-old infants to sequential immunization with Haemophilus influenzae type b-CRM197 conjugate and polysaccharide vaccines.
Rothstein EP; Schiller RP; Girone JA; Hipp TJ; Souder RL; Bernstein HH; Madore DV; Johnson CL; Smith DH
Am J Dis Child; 1991 Aug; 145(8):898-900. PubMed ID: 1858727
[TBL] [Abstract][Full Text] [Related]
4. Prevention of Haemophilus influenzae type b disease.
Santosham M
Vaccine; 1993; 11 Suppl 1():S52-7. PubMed ID: 8447177
[TBL] [Abstract][Full Text] [Related]
5. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants.
Anderson EL; Decker MD; Englund JA; Edwards KM; Anderson P; McInnes P; Belshe RB
JAMA; 1995 Mar; 273(11):849-53. PubMed ID: 7869554
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity study of Haemophilus influenzae type B conjugate vaccine in Indian infants.
Phadke MA; Kulkarni MV; Sovani VB; Lokeshwar MR; Venkataraman R
Indian Pediatr; 1997 Sep; 34(9):779-83. PubMed ID: 9492415
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
Dashefsky B; Wald E; Guerra N; Byers C
Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
[TBL] [Abstract][Full Text] [Related]
8. World-wide strategies for immunization against invasive Haemophilus influenzae type b disease.
Iwarson S
Vaccine; 1993; 11 Suppl 1():S28-9. PubMed ID: 8447169
[TBL] [Abstract][Full Text] [Related]
9. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
[TBL] [Abstract][Full Text] [Related]
10. [When should vaccination against Haemophilus influenzae type b take place?].
Stickl HA
Med Monatsschr Pharm; 1991 Jan; 14(1):24. PubMed ID: 2017108
[No Abstract] [Full Text] [Related]
11. Immunogenicity of Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine in patients who acquired Haemophilus disease despite previous vaccination with type b polysaccharide vaccine.
Granoff DM; Chacko A; Lottenbach KR; Sheetz KE
J Pediatr; 1989 Jun; 114(6):925-33. PubMed ID: 2786062
[TBL] [Abstract][Full Text] [Related]
12. [Vaccination against Haemophilus influenzae].
Huber EG
Padiatr Padol; 1991; 26(4):203-4. PubMed ID: 1749631
[No Abstract] [Full Text] [Related]
13. Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population.
Santosham M; Hill J; Wolff M; Reid R; Lukacs L; Ahonkhai V
Pediatr Infect Dis J; 1991 Feb; 10(2):113-7. PubMed ID: 2062601
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease.
Walter EB; Moggio MV; Drucker RP; Wilfert CM
Pediatr Infect Dis J; 1990 Sep; 9(9):632-5. PubMed ID: 2235187
[TBL] [Abstract][Full Text] [Related]
15. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.
Eskola J; Käyhty H; Takala AK; Peltola H; Rönnberg PR; Kela E; Pekkanen E; McVerry PH; Mäkelä PH
N Engl J Med; 1990 Nov; 323(20):1381-7. PubMed ID: 2233904
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months.
Madore DV; Johnson CL; Phipps DC; Myers MG; Eby R; Smith DH
Pediatrics; 1990 Oct; 86(4):527-34. PubMed ID: 2216616
[TBL] [Abstract][Full Text] [Related]
17. Haemophilus influenzae type B conjugate vaccines.
Force RW; Lugo RA; Nahata MC
Ann Pharmacother; 1992 Nov; 26(11):1429-40. PubMed ID: 1477450
[TBL] [Abstract][Full Text] [Related]
18. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
[TBL] [Abstract][Full Text] [Related]
19. Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine. A cost-effectiveness model of strategy assessment.
Cochi SL; Broome CV; Hightower AW
JAMA; 1985 Jan; 253(4):521-9. PubMed ID: 3918181
[TBL] [Abstract][Full Text] [Related]
20. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
